Since that MF article was written in January, SNY lost a key decision in the Lovenox patent case (#msg-16916457).
SNY is appealing but it's doubtful, IMO, that the ruling will be overturned. In other words, SNY’s US patent exclusivity for Lovenox is likely to expire for good when the appellate court rules, and this should occur in the next year or so.
Note: Sandoz (MNTA’s partner) was not a party to the lawsuit in question, but it is the party to a separate and similar lawsuit vs SNY.
Market Data 
Markets 
AI
